Welcome to our dedicated page for Aldeyra Therapeutics SEC filings (Ticker: ALDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology issuer focused on immune-mediated and metabolic diseases, Aldeyra uses current reports on Form 8-K and periodic reports on Forms 10-K and 10-Q to describe its product candidates, development risks, and key milestones.
In its recent Form 8-K filings, Aldeyra has reported material events such as the extension of the Prescription Drug User Fee Act (PDUFA) target action date for the New Drug Application of topical ocular reproxalap for dry eye disease, the receipt of a Special Protocol Assessment agreement letter from the U.S. Food and Drug Administration for ADX-2191 in primary vitreoretinal lymphoma, and Fast Track Designation for ADX-2191 in retinitis pigmentosa. Other 8-Ks reference press releases on Phase 2 clinical results for ADX-629 in alcohol-associated hepatitis, expansion of the RASP platform into central nervous system diseases, and updates to the company’s pipeline and projected operational cash runway.
Aldeyra’s annual and quarterly reports, referenced in its 8-Ks, include sections such as “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These documents discuss uncertainties related to clinical trial timing, regulatory approvals, potential labeling outcomes, commercialization prospects, competition, reimbursement, and the company’s status as an early-stage developer that may not generate significant revenue.
On this page, AI-powered tools can help summarize lengthy ALDX filings, highlight mentions of key programs like reproxalap and ADX-2191, and surface information on development timelines, regulatory designations, and other disclosures that matter to investors. Users can also review real-time updates as new Aldeyra filings are posted to the SEC’s EDGAR system, including future 10-K, 10-Q, and 8-K reports, as well as any Forms 3, 4, or 5 that may relate to insider transactions.
Aldeyra Therapeutics, Inc. has fully repaid its debt under the Hercules Credit Facility. On April 1, 2026, the company paid off outstanding borrowings of $15 million, and all remaining commitments under the loan agreement were terminated in line with its April 1, 2026 maturity.
The Hercules Credit Facility, originally entered in March 2019, is now fully closed. The company notes that its cash, cash equivalents, and marketable securities as of December 31, 2025 are expected to support operations into 2028, indicating sufficient liquidity after the loan repayment.
Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady received new equity-based compensation awards. He was granted a stock option covering 1,880,510 shares of common stock at an exercise price of $1.77 per share. This option vests in equal monthly installments over 48 months of continuous service after January 1, 2026 and expires on March 26, 2036.
Brady was also awarded 632,318 bonus units, which vest in equal annual installments over four years beginning on March 27, 2026, contingent on continued service. Each vested bonus unit entitles him to a cash payment equal to the closing price per share of Aldeyra’s common stock on the payment date, made on the earlier of four years from grant or a Change of Control. These are compensation grants, not open-market share purchases or sales.
Aldeyra Therapeutics Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned, representing 0% of the Common Stock as disclosed in the amendment.
The filing states Vanguard completed an internal realignment on January 12, 2026 and, "in accordance with SEC Release No. 34-39538 (January 12, 1998)", certain subsidiaries will report ownership separately.
Aldeyra Therapeutics director Richard Douglas bought more company stock in the open market. He acquired 70,000 shares of common stock in an open-market purchase at $1.40 per share. Following this transaction, he directly owns 195,000 shares, indicating a larger personal stake in Aldeyra Therapeutics.
Aldeyra Therapeutics, Inc. Principal Financial Officer Michael Alfieri reported an open-market purchase of common stock. On this transaction date, he bought 5,000 shares at a price of $1.42 per share. Following the purchase, his direct ownership increased to 7,500 common shares.
Aldeyra Therapeutics received a Complete Response Letter from the U.S. FDA for its reproxalap New Drug Application to treat the signs and symptoms of dry eye disease. The FDA wrote that the application lacks substantial evidence of efficacy, citing inconsistent study results and questioning the reliability of positive findings.
No safety or manufacturing concerns were identified, but the FDA concluded that the totality of clinical evidence does not support effectiveness. Aldeyra plans to request a Type A meeting to understand what is required for potential approval and acknowledges that additional studies or trials could be required, which would increase costs and delay commercialization. As of December 31, 2025, the company held $70 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2028.
Aldeyra Therapeutics outlines its strategy as a late‑stage biotechnology company developing RASP modulators and the intravitreal methotrexate product ADX‑2191 for immune‑mediated eye and systemic diseases. Lead candidate reproxalap targets dry eye disease and allergic conjunctivitis, but has received multiple FDA Complete Response Letters requiring additional symptom‑focused trials.
The company has granted AbbVie an exclusive option to co‑develop and commercialize reproxalap, which, if exercised, would include a $100.0 million upfront payment (offset by prior option fees) and up to about $300.0 million in milestones, plus a 60/40 U.S. profit‑share and ex‑U.S. royalties. ADX‑2191 holds orphan and fast track designations in certain indications, with an FDA‑agreed SPA for primary vitreoretinal lymphoma and expansion plans in retinitis pigmentosa.
Perceptive Advisors and affiliates report a 7.0% stake in Aldeyra Therapeutics, Inc. They beneficially own 4,185,632 shares of common stock, based on 60,162,773 shares outstanding as of November 4, 2025. The Perceptive Life Sciences Master Fund directly holds the shares, with Perceptive Advisors as investment manager and Joseph Edelman as managing member.
The reporting persons state that the securities were not acquired and are not held for the purpose of changing or influencing control of Aldeyra, consistent with a passive investment under Schedule 13G.
Aldeyra Therapeutics, Inc. reported that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) date for topical ocular reproxalap, an investigational drug candidate for the treatment of signs and symptoms of dry eye disease. The update relates to the ongoing review of the new drug application for reproxalap.
The company issued a press release on December 15, 2025 describing the PDUFA extension and plans to discuss the news on a conference call on December 16, 2025. Aldeyra also includes detailed forward-looking statements about the timing and outcome of regulatory action, the potential labeling and commercial opportunity for reproxalap, and numerous clinical, regulatory, commercial, and financing risks that could cause actual results to differ from current expectations.
Aldeyra Therapeutics (ALDX) announced an R&D webcast and materials. On November 13, 2025, the company is presenting a slide deck at its 2025 Research & Development Webcast, furnished as Exhibit 99.1.
In a related press release filed as Exhibit 99.2, Aldeyra highlights two updates: expansion of its RASP platform to include central nervous system diseases, and manufacturing updates on reproxalap, its first-in-class investigational candidate for the signs and symptoms of dry eye disease.
The company notes forward-looking statements regarding development timelines, regulatory outcomes, and commercialization are subject to risks and uncertainties. Information furnished under Item 7.01 is not deemed “filed” or subject to Section 18 of the Exchange Act.